Pipeline Progress at Pluristem - Analyst Blog

Comment

Shutterstock photo

Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized.

Pluristem Therapeutics, Inc . ( PSTI ) develops placenta-based cell therapies in collaboration with companies like United Therapeutics ( UTHR ) or through research and clinical institutions. The cells from placenta are derived using the company's proprietary PluriX therapy and are known as PLX cells.

Pluristem intends to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration.

Pluristem recently announced that it has submitted its application to the U.S. Food and Drug Administration (FDA) to grant orphan drug designation to its PLacental eXpanded (PLX-PAD) cells for the treatment of severe preeclampsia.

We note that Pluristem's PLX cells already enjoys orphan drug designation in the U.S. for the treatment of aplastic anemia and Buerger's disease.

The orphan drug designation will not only accelerate the development of PLX cells but will also benefit Pluristem in various stages of drug development, including faster approval process, seven years of marketing exclusivity following marketing approval and tax credits on certain clinical trials in the U.S.

We are encouraged by Pluristem's efforts to develop PLX cells for various diseases. 

Pluristem currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the same sector include Alexion Pharmaceuticals ( ALXN ) and Biogen Idec Inc. ( BIIB ). Both stocks carry a Zacks Rank #1 (Strong Buy).



ALEXION PHARMA (ALXN): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

PLURISTEM THERA (PSTI): Free Stock Analysis Report

UTD THERAPEUTIC (UTHR): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: Investing , Business , Stocks
More Headlines for: ALXN , BIIB , PSTI , UTHR


More from Zacks.com

Subscribe






Zacks.com
Contributor:

Zacks.com

Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com